Nexalin 15 mA Neurostimulation Device Shows Promise in Treating Gambling and Alcohol Use Disorders

Reuters11-18

Nexalin 15 mA Neurostimulation Device Shows Promise in Treating Gambling and Alcohol Use Disorders

Nexalin Technology Inc. has announced the publication of an independent, peer-reviewed case report in The American Journal on Addictions evaluating the company's 15 mA neurostimulation device for treating gambling disorder with alcohol use comorbidity. The case was conducted at the Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, using Nexalin's non-invasive device, which delivered a 15 mA current at 77.5 Hz for 40 minutes per session. The study, registered on ClinicalTrials.gov (Identifier: NCT06195995), reported significant clinical improvement and sustained abstinence following treatment. The authors concluded that larger, controlled trials are warranted to further evaluate the device's efficacy in treating addiction comorbidities and other psychiatric disorders. These results have already been published and presented in the peer-reviewed journal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9577900-en) on November 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584538499?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584538499","market":"us","top_or_hot":-1,"title":"Nexalin 15 mA Neurostimulation Device Shows Promise in Treating Gambling and Alcohol Use Disorders","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nexalin 15 mA Neurostimulation Device Shows Promise in Treating Gambling and Alcohol Use Disorders\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nexalin Technology Inc. has announced the publication of an independent, peer-reviewed case report in The American Journal on Addictions evaluating the company's 15 mA neurostimulation device for treating gambling disorder with alcohol use comorbidity. The case was conducted at the Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, using Nexalin's non-invasive device, which delivered a 15 mA current at 77.5 Hz for 40 minutes per session. The study, registered on ClinicalTrials.gov (Identifier: NCT06195995), reported significant clinical improvement and sustained abstinence following treatment. The authors concluded that larger, controlled trials are warranted to further evaluate the device's efficacy in treating addiction comorbidities and other psychiatric disorders. These results have already been published and presented in the peer-reviewed journal.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9577900-en) on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nexalin 15 mA Neurostimulation Device Shows Promise in Treating Gambling and Alcohol Use Disorders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNexalin 15 mA Neurostimulation Device Shows Promise in Treating Gambling and Alcohol Use Disorders\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-18 22:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nexalin 15 mA Neurostimulation Device Shows Promise in Treating Gambling and Alcohol Use Disorders\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nexalin Technology Inc. has announced the publication of an independent, peer-reviewed case report in The American Journal on Addictions evaluating the company's 15 mA neurostimulation device for treating gambling disorder with alcohol use comorbidity. The case was conducted at the Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, using Nexalin's non-invasive device, which delivered a 15 mA current at 77.5 Hz for 40 minutes per session. The study, registered on ClinicalTrials.gov (Identifier: NCT06195995), reported significant clinical improvement and sustained abstinence following treatment. The authors concluded that larger, controlled trials are warranted to further evaluate the device's efficacy in treating addiction comorbidities and other psychiatric disorders. These results have already been published and presented in the peer-reviewed journal.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9577900-en) on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL6XzNhx:1","article_id":"2584538499","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584538499","pubTimestamp":1763474412,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nexalin Technology Inc. has announced the publication of an independent, peer-reviewed case report in The American Journal on Addictions evaluating the company's 15 mA neurostimulation device for treating gambling disorder with alcohol use comorbidity. The case was conducted at the Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, using Nexalin's non-invasive device, which delivered a 15 mA current at 77.5 Hz for 40 minutes per session. The study, registered on ClinicalTrials.gov , reported significant clinical improvement and sustained abstinence following treatment. The authors concluded that larger, controlled trials are warranted to further evaluate the device's efficacy in treating addiction comorbidities and other psychiatric disorders. These results have already been published and presented in the peer-reviewed journal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pro","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4082":"医疗保健设备","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","NXL":"Nexalin Technology, Inc.","BK4112":"金融交易所和数据","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"Nexalin 15 mA神经刺激装置在治疗赌博和酒精使用障碍方面显示出前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"NXL":0.9},"content_text":"Nexalin 15 mA Neurostimulation Device Shows Promise in Treating Gambling and Alcohol Use Disorders\n    \n\n        Nexalin Technology Inc. has announced the publication of an independent, peer-reviewed case report in The American Journal on Addictions evaluating the company's 15 mA neurostimulation device for treating gambling disorder with alcohol use comorbidity. The case was conducted at the Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, using Nexalin's non-invasive device, which delivered a 15 mA current at 77.5 Hz for 40 minutes per session. The study, registered on ClinicalTrials.gov (Identifier: NCT06195995), reported significant clinical improvement and sustained abstinence following treatment. The authors concluded that larger, controlled trials are warranted to further evaluate the device's efficacy in treating addiction comorbidities and other psychiatric disorders. These results have already been published and presented in the peer-reviewed journal.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9577900-en) on November 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584538499","isCrawlerRequest":true}